Anticorps Polyclonal de lapin anti-NFKB2,p100

• Phare
• Validé par KD/KO

NFKB2,p100 Polyclonal Antibody for WB, IP, IF, IHC, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, IHC, IF/ICC, IP, ELISA

Conjugaison

Non conjugué

Publications

20

N° de cat : 10409-2-AP

Synonymes

DNA binding factor KBF2, H2TF1, LYT 10, LYT10, NF kappa B, NFKB2, NFKB2,p100, Oncogene Lyt 10, p100

---

Galerie de données de validation

• 

  WB analysis using 10409-2-AP

  WB result of 10409-2-AP (NFKB2,p100 antibody).

• 

  WB analysis of HeLa using 10409-2-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 10409-2-AP (NFKB2,p100 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  IP experiment of K-562 using 10409-2-AP

  IP result of anti-NFKB2,p100 (IP:10409-2-AP, 4ug; Detection:10409-2-AP 1:600) with K-562 cells lysate 1200ug.

• 

  IHC staining of human liver cancer using 10409-2-AP

  Immunohistochemical analysis of paraffin-embedded human liver cancer tissue slide using 10409-2-AP (NFKB2,p100 Antibody) at dilution of 1:50 (under 40x lens).

• 

  IHC staining of human pancreas cancer using 10409-2-AP

  Immunohistochemical analysis of paraffin-embedded human pancreas cancer tissue slide using 10409-2-AP (NFKB2,p100 Antibody) at dilution of 1:50 (under 40x lens).

• 

  IHC staining of human liver cancer using 10409-2-AP

  Immunohistochemical analysis of paraffin-embedded human liver cancer tissue slide using 10409-2-AP (NFKB2,p100 Antibody) at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human pancreas cancer using 10409-2-AP

  Immunohistochemical analysis of paraffin-embedded human pancreas cancer tissue slide using 10409-2-AP (NFKB2,p100 Antibody) at dilution of 1:50 (under 10x lens).

• 

  IF Staining of HeLa using 10409-2-AP

  Immunofluorescent analysis of HeLa cells using 10409-2-AP (NFKB2,p100 antibody) at dilution of 1:25 and Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

---

Applications testées

• Résultats positifs en WB: cellules HeLa, cellules Jurkat, cellules K-562
• Résultats positifs en IP: cellules K-562
• Résultats positifs en IHC: tissu de cancer du pancréas humain, tissu de cancer du foie humain; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.
• Résultats positifs en IF/ICC: cellules HeLa

Dilution recommandée

• Western Blot (WB): WB : 1:500-1:1000
• Immunoprécipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunohistochimie (IHC): IHC : 1:20-1:200
• Immunofluorescence (IF)/ICC: IF/ICC : 1:10-1:100

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 1 publications below
• WB: See 15 publications below
• IHC: See 8 publications below
• IF: See 2 publications below

Informations sur le produit

10409-2-AP cible NFKB2,p100 dans les applications de WB, IHC, IF/ICC, IP, ELISA et montre une réactivité avec des échantillons Humain, rat, souris

• Réactivité: Humain, rat, souris
• Réactivité citée: rat, Humain, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: NFKB2,p100 Protéine recombinante Ag0662
• Nom complet: nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
• Masse moléculaire calculée: 97 kDa
• Poids moléculaire observé: 100-110 kDa
• Numéro d’acquisition GenBank: BC002844
• Symbole du gène: NFKB2
• Identification du gène (NCBI): 4791
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. P52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. P52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. This antibody can bind p100 isoform of NFKB2 spefically, but not p52 isoform.

Publications

Species	Application	Title
mouse	WB	Nat Commun; A proteomics landscape of circadian clock in mouse liver.; Authors - Yunzhi Wang
human	WB	Nat Commun; A translational program that suppresses metabolism to shield the genome.; Authors - Nathan C Balukoff
mouse	WB	J Hazard Mater; TiO2 nanosheets promote the transformation of vascular smooth muscle cells into foam cells in vitro and in vivo through the up-regulation of nuclear factor kappa B subunit 2.; Authors - Shuang Li
human	WB	PLoS Pathog; SHMT2 and the BRCC36/BRISC deubiquitinase regulate HIV-1 Tat K63-ubiquitylation and destruction by autophagy.; Authors - Muyu Xu
human	WB,IHC	Biochim Biophys Acta Mol Basis Dis; LRRC8A as a central mediator promotes colon cancer metastasis by regulating PIP5K1B/PIP2 pathway; Authors - Haifeng Zhang
human	WB	Cell Death Dis; Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma.; Authors - Xinhua Xiao